Press Releases Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Delayed Japan Exchange Other stock markets 07:00:00 26/04/2024 BST			5-day change	1st Jan Change
4,089 ^JPY	-0.02%		-0.94%	+0.86%

04-26	EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	MT
04-26	Hutchmed notes CHMP's positive opinion for fruiquintinib approval	AN

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	04-29	AQ
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	04-26	BU
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	04-19	AQ
Takeda to Hold Fiscal Year 2023 Earnings Call on May 9	04-19	AQ
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease	04-19	BU
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food	04-08	BU
Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	03-27	AQ
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting	03-26	BU
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	03-26	BU
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG in Adult Patients with Newly Diagnosed Ph+ ALL	03-20	AQ
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL	03-19	BU
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab, a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia	03-14	AQ
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia	03-13	BU
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas	02-27	BU
Championing Rare Voices on Rare Disease Day	02-26	AQ
FDA Approves Takeda's EOHILIA, the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis	02-13	AQ
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)	02-12	BU
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024	02-08	BU
Takeda Announces FY2023 Q3 Results, On-track towards Full-Year Management Guidance with Strong Momentum in Growth and Launch Products	02-02	AQ
Takeda Announces Chief Financial Officer Succession	02-01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Press Releases

Filters